Navigation Links
Oxford BioMedica Announces Ocular Programme Update
Date:6/22/2011

plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.  The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include Sanofi, Sigma-Aldrich and Pfizer.  Further information is available at http://www.oxfordbiomedica.co.uk.

2. Oxford BioMedica's agreement with Sanofi

Under the terms of the agreement signed with Sanofi in April 2009, Oxford BioMedica is responsible for the pre-clinical and initial Phase I/II studies of four lentiviral vector-based product candidates in the field of ophthalmology: RetinoStat® for "wet" AMD, StarGen™ for Stargardt disease, UshStat® for Usher syndrome 1B and EncorStat® for corneal graft rejection.  Oxford BioMedica granted Sanofi a license to develop the products and an option for further development, manufacture and commercialisation on a worldwide basis.  At any time prior to or within a defined period after completion of each Phase I/II study, Sanofi can exercise its option to license the products and will then assume responsibility for on-going activities.  Sanofi also has rights to broaden its license to develop the four products in additional indications, and has rights of first refusal to license other lentiviral vector-based products for the treatment of ocular diseases.

3. LentiVector® gene delivery technology

Oxford Bio
'/>"/>

SOURCE Oxford Biomedica Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
2. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
3. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
4. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
5. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
6. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
7. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
8. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
9. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
10. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
11. Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... GRAFTON, Wis. , May 4, 2015 /PRNewswire/ ... of high-quality consumables used in dental restorative procedures, ... is a producer of an innovative sectional matrix ... "We are excited about the opportunity to ... accessories," said John Frymark , VP and ...
(Date:5/4/2015)... , May 4, 2015  Fox Three Partners, ... on the lower middle market, announced today the ... in 1969 and based in Newport ... range of radiation products for medical professionals as ... with Peninsula Capital Partners ("Peninsula"), an investment company ...
(Date:5/4/2015)...   The New York Times sought out ... plastic surgeon, Dr. Rod Rohrich . Kybella, recently ... to reduce fat deposits under the chin. ... active ingredient in Kybella, deoxycholic acid, dissolves the fat ... to reshape this area without surgery. "So many consumers ...
Breaking Medicine Technology:Microbrush International Announces Acquisition of DentiSmart 2Fox Three Partners, LLC Acquires Burlington Medical Supplies, Inc. 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 3
... 2010 Valeant Pharmaceuticals International, Inc. (NYSE: ... Board of Directors (the "Board") has declared a one-time ... Dividend") that shareholders of record as of the close ... will be entitled to receive on December 22, 2010. ...
... Ind., Nov. 3, 2010 Symmetry Medical Inc. (NYSE: ... the global orthopaedic device industry and other medical markets, announced ... secured revolving credit facility, effective November 3, 2010.  The credit ... borrowing capacity up to $300 million. The credit facility has ...
Cached Medicine Technology:Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan 2Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan 3Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan 4Symmetry Medical Closes $200 Million Credit Facility 2Symmetry Medical Closes $200 Million Credit Facility 3
(Date:5/5/2015)... May 05, 2015 Buckeye Health Plan ... new CEO and plan president of Buckeye Health Plan. ... the position immediately. , Hill has more than 28 ... the Pacific Northwest, from managed care to large health ... and CEO of HealthPlus of Michigan, a health plan ...
(Date:5/5/2015)... San Francisco, California (PRWEB) May 05, 2015 ... company based in San Francisco, leads an international initiative ... in order to extend the human lifespan. Scientists ... clocks inherent to women, from the initiation of her ... reveal a possible mechanism for aging and, ultimately, extend ...
(Date:5/5/2015)... May 05, 2015 HealthSlide, ... innovative interoperability solutions for hospitals nationwide, has announced ... calculator. Hospital CIOs and CTOs can access the ... calculator shows both initial and ongoing savings of ... , “Our nation’s hospitals pay an average of ...
(Date:5/5/2015)... 05, 2015 After record-breaking sales of ... 2014, Walgreens introduces the Cookies & Cream flavor at ... Extend Nutrition has continually raised the bar for nutritional ... combined with an unprecedented nutritional profile, backed by international ... Extend Nutrition will launch additional new products and expand ...
(Date:5/5/2015)... OR (PRWEB) May 05, 2015 Every year, ... eye seasons. Turns out, the worst dry eye season is ... count spikes in most of the United States. The only ... Fresh water advocate Sharon Kleyne, host of the Sharon Kleyne ... eye on her radio show of May 11, 2015. Kleyne ...
Breaking Medicine News(10 mins):Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:HealthSlide Launches ROI Cost Calculator 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... International, http://www.heifer.org, a world hunger organization, provides ... the hard-to-shop-for,person who says, "Please, no more stuff!" ... one thing well: Helping impoverished families who,are among ... $2 a day gain better,livelihoods by providing livestock ...
... Designs for Health, Inc., a leading provider of science-based nutritional ... practice management software packages-- eHealthPro™ and eNatro™--from Enova Inc, a ... ... Windsor, CT (PRWEB) October 20, 2008 -- Designs for Health, ...
... edge whitening system. Manhattan dentist claims Pearlinbrite is more effective ... effective and precise than other options. , ... New ... spent the last 25 years developing Pearlinbrite, a unique in-office laser ...
... of treatment received have an impact on a non-Hodgkin lymphoma ... a new study published in the December 1, 2008 issue ... Cancer Society. The study reveals that poorer socioeconomic status increases ... risk. , NHL is a common type of cancer in ...
... feature story on Mary Hall will appear on http://fortlauderdalecitylimits.com . ... ... -- Mary Hall, CEO of iHealthspot, Inc. a leading provider of ... Fort Lauderdale City Limits "Profiles of Excellence" in the Advertising & ...
... Oct. 17 In the U.S., approximately one,in eight ... about 1.2,million couples visit a fertility specialist for help ... must-have, go-to resource for any woman who,wants to keep ... --,now, soon, or later. Conceive,s readers are thinking about ...
Cached Medicine News:Health News:Heifer International: The Greener Good for Holiday Giving 2Health News:Designs for Health Acquires eHealthPro™ and eNatro™ Practice Management Software 2Health News:Designs for Health Acquires eHealthPro™ and eNatro™ Practice Management Software 3Health News:Designs for Health Acquires eHealthPro™ and eNatro™ Practice Management Software 4Health News:Dr. Jan Linhart Now Offerring Unique Laser Teeth Whitening System 2Health News:Socioeconomic and treatment factors affect non-Hodgkin lymphoma patients' survival 2Health News:Mary Hall, CEO of iHealthSpot, Inc., is Awarded Membership Into Fort Lauderdale City Limits "Profiles of Excellence" 2Health News:Conceive Magazine Introduces a Special Issue: 'The Birds, The Bees, and Modern Medicine' 2
... Agarose, Molecular Biology Grade, is ... of nucleic acids. It can ... fragments from 0.2 to 40 ... Agarose is tested and certified ...
... is specifically formulated for high resolution of ... bp. This standard melting temperature agarose can ... 10 bp difference in size. UltraPure™ ... structure for better handling and improved clarity ...
Agarose IEF is suitable for isoelectric focusing of large molecules and is the gel of choice for many IEF applications and immunochemical detection methods....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Medicine Products: